REDWOOD CITY, CA, USA I April 14, 2025 I Pheast Therapeutics, a private biotechnology company developing novel therapies to unleash the power of macrophages ...

LARKSPUR, CA, USA I April 14, 2025 I Aulos™ Bioscience, an immuno-oncology company working to revolutionize cancer care through development of ...

NEW YORK, NY, USA I April 14, 2025 I Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral ...

PRINCETON, NJ, USA I April 14, 2025 I Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the ...

INGELHEIM, Germany, and BOSTON, MA, USA I April 14, 2025 I Boehringer Ingelheim and Cue Biopharma, Inc. (Nasdaq: CUE) today announced a strategic research ...

PARIS, France I April 15, 2025 I Sanofi today shared new progress from its mid- to late-stage respiratory pipeline, including preliminary phase 2 results for ...

BASEL, Switzerland I April 14, 2025 I Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Columvi® (glofitamab) in ...

ISELIN, NJ, USA I April 08, 2025 I Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for ...

First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy ...

SAINT HERBLAIN, France and SCHLIEREN, Zurich I April 9, 2025 I Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech ...

YANTAI, China I April 8, 2025 I On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and ...

BUSAN, South Korea I April 09, 2025 I NexThera Co., Ltd. (CEO:SaeGwang Park) announced on April 9th that it has completed the first patient enrollment for its ...